NCT07187375View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 28, 2025

Primary Completion Date

September 6, 2029

Study Completion Date

October 4, 2029

Conditions
Congenital Adrenal Hyperplasia
Interventions
DRUG

Crinecerfont

Oral solution

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY